Overview of diagnosis and management of metastatic disease to bone

Cancer Control

Volumn 19, Issue 2, 2012, Pages 84-91

  Yu, Hsiang Hsuan Michael ^a   Tsai, Ya Yu ^a   Hoffe, Sarah E ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; SAMARIUM 153;

BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; BONE RADIOGRAPHY; CANCER RADIOTHERAPY; CLINICAL FEATURE; DIAGNOSTIC IMAGING; HUMAN; INTERMETHOD COMPARISON; PATIENT SELECTION; PERSONALIZED MEDICINE; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMIC THERAPY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 84859464875     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201900202     Document Type: Review

References (71)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584-593.
2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55(1):61-66.
3. Resnick D, Niwayama G. Skeletal metastases. In: Resnick D, Niwayama G, eds. Diagnosis of Bone and Joint Disorders. 2nd ed. Philadelphia, PA: WB Saunders; 1988:3945-4010.
4. Higinbotham NL, Marcove RC. The management of pathological fractures. J Trauma. 1965;5(6):792-798.
5. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655-1664.
6. Roila F, Lupattelli M, Sassi M, et al. Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. Ann Oncol. 1991;2(6):437-439.
7. Takashi M, Takagi Y, Sakata T, et al. Surgical treatment of renal cell carcinoma metastases: prognostic significance. Int Urol Nephrol. 1995;27(1):1-8.
8. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643-648.
9. Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer. 1997;80(8 suppl):1595-1607.
10. Schaffer DL, Pendergrass HP. Comparison of enzyme, clinical, ra-diographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology. 1976;121(2):431-434.
11. Ludwig H, Kumpan W, Sinzinger H. Radiography and bone scintigraphy in multiple myeloma: a comparative analysis. Br J Radiol. 1982;55(651):173-181.
12. Woolfenden JM, Pitt MJ, Durie BG, et al. Comparison of bone scintigraphy and radiography in multiple myeloma. Radiology. 1980;134(3): 723-728.
13. Ryan PJ, Fogelman I. The bone scan: where are we now? Semin Nucl Med. 1995;25(2):76-91.
14. Savelli G, Maffioli L, Maccauro M, et al. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45(1):27-37.
15. Schweitzer ME, Levine C, Mitchell DG, et al. Bull's-eyes and halos: useful MR discriminators of osseous metastases. Radiology. 1993;188(1): 249-252.
16. Uchida N, Sugimura K, Kajitani A, et al. MR imaging of vertebral metastases: evaluation of fat saturation imaging. Eur J Radiol. 1993;17(2): 91-94.
17. Pomeranz SJ, Pretorius HT, Ramsingh PS. Bone scintigraphy and multimodality imaging in bone neoplasia: strategies for imaging in the new health care climate. Semin Nucl Med. 1994;24(3):188-207.
18. Kao CH, Hsieh JF, Tsai SC, et al. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res. 2000;20(3B):2189-2192.
19. Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003;38(5):250-256.
20. Fogelman I, Cook G, Israel O, et al. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35(2):135-142.
21. Grant FD, Fahey FH, Packard AB, et al. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49(1):68-78.
22. Even-Sapir E, Mishani E, Flusser G, et al. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med. 2007;37(6):462-469.
23. Hetzel M, Arslandemir C, König HH, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003;18(12):2206-2214.
24. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustainedrelease oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage. 1997;13(5):254-261.
25. Cherny N. New strategies in opioid therapy for cancer pain. J Oncol Manag. 2000;9(1):8-15.
26. Cherny NI. The management of cancer pain. CA Cancer J Clin. 2000;50(2):70-116; quiz 117-120.
27. Sloan PA, Moulin DE, Hays H. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage. 1998;16(2):102-111.
28. Kvale PA, Simoff M, Prakash UB. Lung cancer: palliative care. Chest. 2003;123(1 suppl):284S-311S.
29. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107-112.
30. Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J. 2001;7(suppl 3):S120-S128.
31. Saad F, Chi K, Fleshner N. The role of bisphosphonates in the management of bone metastases in prostate cancer. Can J Urol. 2004; 11(5):2376-2382.
32. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735-1744.
33. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90(6):1133-1137.
34. Carteni G, Bordonaro R, Giotta F, et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist. 2006;11(7):841-848.
35. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998;16(12):3890-3899.
36. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-5139.
37. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-1132.
38. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castrationresistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-822.
39. Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007;25(11):1423-1436.
40. Chow E. Update on radiation treatment for cancer pain. Curr Opin Support Palliat Care. 2007;1(1):11-15.
41. Blitzer PH. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer. 1985;55(7):1468-1472.
42. Steenland E, Leer JW, van Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol. 1999;52(2):101-109.
43. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of shortversus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97(11):798-804.
44. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol. 1999;52(2):111-121.
45. Foro Arnalot P, Fontanals AV, Galcerán JC, et al. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol. 2008;89(2):150-155.
46. Jeremic B, Shibamoto Y, Acimovic L, et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int J Radiat Oncol Biol Phys. 1998;42(1):161-167.
47. Kaasa S, Brenne E, Lund JA, et al. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy × 1) versus multiple fractions (3 Gy × 10) in the treatment of painful bone metastases. Radiother Oncol. 2006;79(3):278-284.
48. Koswig S, Budach V. [Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy): a prospective study]. Strahlenther Onkol. 1999;175(10):500-508.
49. Roos DE, Turner SL, O'Brien PC, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol. 2005;75(1):54-63.
50. Sande TA, Ruenes R, Lund JA, et al. Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: results from a randomized multicentre trial. Radiother Oncol. 2009;91(2):261-266.
51. Wu JS, Wong R, Johnston M, et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003;55(3):594-605.
52. Sze WM, Shelley M, Held I, et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials. Cochrane Database Syst Rev. 2004(2):CD004721.
53. Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965-976.
54. Gerszten PC, Burton SA, Ozhasoglu C, et al. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976). 2007;32(2):193-199.
55. Yamada Y, Matsumoto T, Arakawa A, et al. Evaluation using a combination of lymphatic invasion on D2-40 immunostain and depth of dermal invasion is a strong predictor for nodal metastasis in extramammary Paget's disease. Pathol Int. 2008;58(2):114-117.
56. Moulding HD, Elder JB, Lis E, et al. Local disease control after decompressive surgery and adjuvant high-dose single-fraction radiosurgery for spine metastases. J Neurosurg Spine. 2010;13(1):87-93.
57. Jin R, Rock J, Jin JY, et al. Single fraction spine radiosurgery for myeloma epidural spinal cord compression. J Exp Ther Oncol. 2009;8(1): 35-41.
58. Haley ML, Gerszten PC, Heron DE, et al. Efficacy and cost-effectiveness analysis of external beam and stereotactic body radiation therapy in the treatment of spine metastases: a matched-pair analysis. J Neurosurg Spine. 2011;14(4):537-542.
59. Salazar OM, Sandhu T, da Motta NW, et al. Fractionated halfbody irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys. 2001;50(3): 765-775.
60. Roqué I Figuls M, Martinez-Zapata MJ, Scott-Brown M, et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2011;(7):CD003347.
61. Silberstein EB, Taylor AT Jr; EANM. EANM procedure guidelines for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2003;30(3):BP7-BP11.
62. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med. 2010; 40(2):89-104.
63. Perez CA, Cosmatos D, Garcia DM, et al. Irradiation in relapsing carcinoma of the prostate. Cancer. 1993;71(3 suppl):1110-1122.
64. Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol. 1993;20(3 suppl 2):38-43.
65. Heron DE, Brufsky A, Beriwal S, et al. Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy. Ann Oncol. 2008;19(9):1639-1643.
66. Robinson RG, Preston DF, Schiefelbein M, et al. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA. 1995; 274(5):420-424.
67. Vassiliou V, Bruland O, Janjan N, et al. Combining systemic bisphosphonates with palliative external beam radiotherapy or bonetargeted radionuclide therapy: interactions and effectiveness. Clin Oncol (R Coll Radiol). 2009;21(9):665-667.
68. Vassiliou V, Kardamakis D. The management of metastatic bone disease with the combination of bisphosphonates and radiotherapy: from theory to clinical practice. Anticancer Agents Med Chem. 2009;9(3):326-335.
69. Haentjens P, Casteleyn PP, Opdecam P. Evaluation of impending fractures and indications for prophylactic fixation of metastases in long bones: review of the literature. Acta Orthop Belg. 1993;59(suppl 1):6-11.
70. Tancioni F, Lorenzetti MA, Navarria P, et al. Percutaneous vertebral augmentation in metastatic disease: state of the art. J Support Oncol. 2011; 9(1):4-10.
71. Jenis LG, Dunn EJ, An HS. Metastatic disease of the cervical spine: a review. Clin Orthop Relat Res. 1999;(359):89-103.